Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

Publications

Download reprints of research and studies we have submitted to scientific and medical journals.
Click on the link(s) below for more information.

Sedov V, Stuart RK  Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.  Ther Adv Hematol. 2017 Jun;8(6):185-195. doi: 10.1177/2040620717703012. Epub 2017 Apr 21.

Giovanni Luca Gravina, Andrea Mancini, Claudia Mattei, Flora Vitale, Francesco Marampon, Alessandro Colapietro, Giulia Rossi, Luca Ventura, Antonella Vetuschi, Ernesto Di Cesare, Judith A. Fox, Claudio Festuccia  Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.  Oncotarget. 2017; 8:29865-29886. doi: 10.18632/oncotarget.16168

Nijenhuis CM, Lucas L, Rosing H, Huitema AD, Mergui-Roelvink , Jamieson GC, Fox JA, Mould DR, Schellens JH, Beijnen JH  Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.  Invest New Drugs. 2017 Jan 31. doi: 10.1007/s10637-017-0428-1. [Epub ahead of print]

Gene C. Jamieson, Judith A. Fox, Ming Poi, Stephen A. Strickland.  Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.  Drugs. 2016 Sep;76(13):1245-55. doi: 10.1007/s40265-016-0614-z.

F Ravandi, E K Ritchie, H Sayar, JE Lancet, MD Craig, N Vey, SA Strickland, GJ Schiller, E Jabbour, HP Erba, A Pigneux, HA Horst, C Recher, VM Klimek, J Cortes, GJ Roboz, O Odenike, X Thomas, VHavelange, J Maertens, HG Derigs, M Heuser, L Damon, BL Powell, G Gaidano, AM Carella, A Wei, D Hogge, AR Craig, JA Fox, R Ward, JA Smith, G Acton, C Mehta, RK Stuart, HM Kantarjian.  Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.  The Lancet published online: 30 July 2015 (DOI: http://dx.doi.org/10.1016/S1470-2045(15)00201-6)

Anya K Hotinski, Ian D Lewis, David M Ross.  Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.  Expert Opinion on Pharmacotherapy, June 2015, Vol. 16, No. 9 : Pages 1395-1402 (doi: 10.1517/14656566.2015.1044437)

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.  Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.  Expert Opinion on Pharmacotherapy, June 2015, Vol. 16, No. 9 : Pages 1395-1402 (doi: 10.1517/14656566.2015.1044437)

Stuart, R. K., Cripe, L. D., Maris, M. B., Cooper, M. A., Stone, R. M., Dakhil, S. R., Turturro, F., Stock, W., Mason, J., Shami, P. J., Strickland, S. A., Costa, L. J., Borthakur, G., Michelson, G. C., Fox, J. A., Leavitt, R. D. and Ravandi, F.  REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. British Journal of Haematology. doi: 10.1111/bjh.13214.

Jeffrey E. Lancet, Gail J. Roboz, Larry D. Cripe, Glenn C. Michelson, Judith A. Fox, Richard D. Leavitt, Tianling Chen, Rachael Hawtin, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, Judith E. Karp  A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica January 2014:doi:10.3324/haematol.2014.114769

Freeman C, Keane N, Swords R, and Giles F.  Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opinion on Pharmacotherapy. 20 May 2013 [Epub ahead of print].

Jonathan A Abbas, Robert K Stuart.  Vosaroxin: a novel antineoplastic quinolone. Expert Opinion on Investigational Drugs Aug 2012, Vol. 21, No. 8, Pages 1223-1233: 1223-1233.

Gordon IK, Graves C, Kil WJ, Meushaw T, Tofilon P, Camphausen K.  Radiosensitization by the novel DNA intercalating agent vosaroxin. Radiat Oncol. 2012;7:26. In press. Provisional pdf available from: http://www.ro-journal.com/content/pdf/1748-717X-7-26.pdf.

Ritchie EK.  New weapons and strategies in the battle against relapsed acute myeloid leukemia (AML). In:Treatment strategies - hematology. Volume 2, Issue 1. Holcroft R, editor. London: The Cambridge Research Centre; 2012. p. 79 84.

JE Lancet, F Ravandi, RM Ricklis, LD Cripe, HM Kantarjian, FJ Giles, AF List, T Chen, RS Allen, JA Fox, GC Michelson and JE Karp  A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia advance online publication 15 July 2011; doi: 10.1038/leu.2011.157

Walsby EJ, Coles SJ, Knapper S, and Burnett AK. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 2011;96(3):393-399. doi:10.3324/haematol.2010.032680

Krug, Lee M. MD; Crawford, Jeffrey MD; Ettinger, David S. MD; Shapiro, Geoffrey I. MD; Spigel, David MD; Reiman, Tony MD; Temel, Jennifer S. MD; Michelson, Glenn C. MD; Young, Donald Y. MS; Hoch, Ute PhD; Adelman, Daniel C. MD Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer. Journal of Thoracic Oncology:February 2011 - Volume 6 - Issue 2 - pp 384-386

Rachael Elizabeth Hawtin, David Elliot Stockett, Oi Kwan Wong, Cecilia Lundin, Thomas Helleday, Judith Ann Fox Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks. Oncotarget 2010; 1: 606 - 619

Ranjana H. Advani, Herbert I. Hurwitz, Michael S. Gordon, Scot W. Ebbinghaus, David S. Mendelson, Heather A. Wakelee, Ute Hoch, Jeffrey A. Silverman, Nancy A. Havrilla, Craig J. Berman, Judith A. Fox, Roberta S. Allen, Daniel C. Adelman.(2010) Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. Clin Cancer Res April 1, 2010 16:2167-2175

Hawtin RE, Stockett DE, Byl JAW, McDowell RS, Tan N, et al.(2010) Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II. PLoS ONE 5(4): e10186. doi:10.1371/journal.pone.0010186

Scatena CD, Kumer JL, Arbitrario JP, Howlett AR, Hawtin RE, Fox JA, Silverman JA. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemotherapy and Pharmacology, Volume 66, Number 5, 881-888

Fathi AT, Karp JE. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep. 2009 Sep;11(5):346-52.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. Epub 2008 Oct 19.

Mills DA, Fekrazad HM, Verschraegen CF. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers. Curr Opin Investig Drugs. 2008 Jun;9(6):647-57. Review.

Tsuzuki Y, Tomita K, Shibamori K, Sato Y, Kashimoto S, Chiba K. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 2. J Med Chem. 2004 Apr 8;47(8):2097-109.

Evanchik MJ, Allen D, Yoburn JC, Silverman JA, Hoch U. Metabolism of (+)-1,4-dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (voreloxin; formerly SNS-595), a novel replication-dependent DNA-damaging agent.Drug Metab Dispos. 2009 Mar;37(3):594-601. Epub 2008 Dec 12.